Additionally, response to induction systemic therapy, serum CRP level, and older age at diagnosis (≥75 years) could be used as a prognostic factor instead of cachexia or sarcopenia, and in turn they could play a fundamental role in selecting patients with sOMD fit for radical treatment. The gene discussed is CRP; the disease is sarcopenia.